Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 13/20 | 0.63 |
| ▸ | ACP1 | P24666 | 3/20 | 0.56 |
| ▸ | PDE5A | O76074 | 3/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459952 | 1.00 | GBA1 (0.63) | GBA1ACP1PDE5AABCG2MEN1 | |
| SCHEMBL3460107 | 0.93 | GBA1 (0.66) | GBA1ACP1PDE5AABCG2 | |
| SCHEMBL3459386 | 0.93 | GBA1 (0.66) | GBA1ACP1PDE5AABCG2 | |
| SCHEMBL3460116 | 0.90 | GBA1 (0.68) | GBA1 | |
| SCHEMBL3461097 | 0.90 | GBA1 (0.68) | GBA1 | |
| SCHEMBL3460493 | 0.87 | GBA1 (0.53) | GBA1ACP1PDE5AAURKARPS6KB1 | |
| SCHEMBL5565597 | 0.85 | ADORA3 (0.52) | GBA1PDE5AABCG2MEN1KMT2A | |
| SCHEMBL3460118 | 0.85 | ADORA3 (0.52) | GBA1PDE5AABCG2MEN1KMT2A | |
| SCHEMBL3460150 | 0.85 | ADORA3 (0.52) | GBA1PDE5AABCG2MEN1KMT2A | |
| SCHEMBL5565602 | 0.85 | ADORA3 (0.52) | GBA1PDE5AABCG2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | GBA1 4763/4885ACP1 1276/4885PDE5A 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.